Immunogenicity of aerosolised Ad5-nCoV in healthy adults.

Shen Wang*

Department of Epidemiology, Nanjing Medical University, China

Introduction

In the ongoing battle against the COVID-19 pandemic, vaccines have emerged as powerful tools to curb the spread of the virus and protect human health. Among the various COVID-19 vaccine candidates, Ad5-nCoV, developed by CanSino Biologics, has garnered attention for its unique aerosolized delivery method. This article explores the immunogenicity of aerosolized Ad5-nCoV in healthy adults, shedding light on the potential benefits and challenges associated with this innovative approach [1].

Traditional vaccines are administered through injections, delivering the vaccine's antigens directly into the bloodstream. However, aerosolized vaccines take a different route. They are inhaled into the respiratory system, where the vaccine's antigens are presented to the immune system through the mucosal surfaces of the respiratory tract. Ad5-nCoV, based on an adenovirus vector, is one such vaccine that has been adapted for aerosolized delivery. This approach offers several advantages, including ease of administration, potential cost savings, and the ability to induce both systemic and mucosal immune responses. Moreover, aerosolized vaccines like Ad5-nCoV hold promise for addressing respiratory infections like COVID-19 more effectively [2].

Immunogenicity is a crucial aspect of vaccine evaluation, as it assesses the vaccine's ability to provoke an immune response. In the case of aerosolized Ad5-nCoV, studies have focused on healthy adults to determine its effectiveness in stimulating immune defenses against the SARS-CoV-2 virus. Early clinical trials have shown promising results regarding the immunogenicity of aerosolized Ad5-nCoV. These trials typically measure the production of antibodies, specifically neutralizing antibodies, which can block the virus from entering human cells. In healthy adults, aerosolized Ad5-nCoV has demonstrated the capacity to induce a robust production of neutralizing antibodies [3].

Furthermore, the vaccine's aerosolized delivery directly targets the respiratory mucosa, an entry point for respiratory viruses like SARS-CoV-2. This localized immune response in the respiratory tract could contribute to enhanced protection against COVID-19 by preventing the virus from establishing infection in the first place. While the immunogenicity of aerosolized Ad5-nCoV in healthy adults appears promising, several challenges and considerations must be acknowledged. Inhalation of vaccine particles may raise concerns about respiratory adverse effects. Ensuring the safety of aerosolized vaccines is paramount, especially in individuals with underlying respiratory conditions [4].

Aerosolized vaccines may require specialized equipment for administration and storage, potentially limiting their accessibility in certain regions. It remains to be seen how long the immune response induced by aerosolized Ad5-nCoV persists. Long-term studies are necessary to assess the durability of protection. The emergence of new SARS-CoV-2 variants raises questions about whether aerosolized Ad5-nCoV can effectively combat these variants. Ongoing research is essential to address this concern [5].

Conclusion

Aerosolized Ad5-nCoV represents an innovative approach to COVID-19 vaccination. Its ability to induce a robust immune response in healthy adults, particularly at mucosal surfaces, holds promise for enhanced protection against the virus. However, challenges related to safety, distribution, durability of immunity, and variants of concern must be addressed. As research into aerosolized Ad5-nCoV continues, it could offer a valuable tool in the fight against the COVID-19 pandemic. The immunogenicity of this novel vaccine in healthy adults underscores the importance of exploring diverse vaccination strategies to achieve widespread immunity and ultimately bring an end to this global health crisis.

References

1. Jin L, Tang R, Wu S, et al. Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial. Emerg Microbes Infect. 2023;12(1):2155251.
2. Intawong K, Chariyalertsak S, Chalom K, et al. Reduction in severity and mortality in COVID-19 patients owing to heterologous third and fourth-dose vaccines during the periods of delta and omicron predominance in Thailand. Int J Infect Dis. 2023;126:31-8.
3. Wang J, Deng C, Liu M, et al. A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain. Nat Commun. 2022;13(1):6866.
4. Sprangers MC, Lakhai W, Koudstaal W, et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and

***Correspondence to:** Shen Wang, Department of Epidemiology, Nanjing Medical University, China, E-mail: shenwang@njmu.edu.cn

***Received:** 02-Jan-2024, Manuscript No. AAICR-23-115699; **Editor assigned:** 03-Jan-2024, Pre QC No. AAICR-23-115699(PQ); **Reviewed:** 17-Jan-2024, QC No. AAICR-23-115699; **Revised:** 25-Jan-2024, Manuscript No. AAICR-23-115699(R); **Published:** 27-Jan-2024, DOI: 10.35841/aaicr-7.1.170*

***Citation:** Wang S. Immunogenicity of aerosolised Ad5-nCoV in healthy adults. Immunol Case Rep. 2024;7(1):170*

gene therapy vectors. J Clin Microbiol. 2003;41(11):5046-52.

5. Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. The Lancet. 2020;395(10240):1845-54.